Online first
Research paper
Published online: 2022-10-27

open access

Page views 606
Article views/downloads 345
Get Citation

Connect on Social Media

Connect on Social Media

Diagnostic accuracy of serum human epididymis protein 4 in ovarian cancer patients with different ethnic groups and menopausal status: a meta-analysis and systematic evaluation

Rui Sun1, Lin Liu2, Zhengli Feng1, Ao Ni3, Qing Guo1

Abstract

Objectives: We aimed to analyze and evaluate the diagnostic value of serum human epididymis protein 4 (HE4) in ovarian cancer (OC) of patients with different menopausal status.

Material and methods: A comprehensive electronic and manual search of the relevant literature was performed through several databases such as CNKI, Wanfang database, VIP database, Chinese biomedical database, web of science, PubMed, EMBASE, and Cochrane database. We collected Chinese and English articles to assess the diagnostic value of HE4 for ovarian cancer in female with different menopausal status. The quality of the studies included in the systematic review was assessed using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool.

Results: A total of 14 publications were included in this study and we didn’t find publication bias in them. The sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio of HE4 for the diagnosis of ovarian cancer in postmenopausal vs. premenopausal female were 0.71 (95% CI, 0.63–0.78) vs 0.78 (95% CI, 0.74–0.81); 0.91 (95% CI, 0.85–0.95) vs 0.90 (95% CI, 0.86–0.93); 11.90 (95% CI, 6.42–22.07) vs 11.03 (95% CI, 6.44–18.89); and 0.30 (95% CI, 0.22–0.39) vs 0.24 (95% CI, 0.20–0.29), respectively.

Conclusions: Serum HE4 has greater diagnostic value in detecting ovarian cancer, especially in Asian postmenopausal female.

Article available in PDF format

View PDF Download PDF file

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1): 7–34.
  2. Park HK, Ruterbusch JJ, Cote ML. Recent trends in ovarian cancer incidence and relative survival in the united states by race/ethnicity and histologic subtypes. Cancer Epidemiol Biomarkers Prev. 2017; 26(10): 1511–1518.
  3. Clauss A, Lilja H, Lundwall A. A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to whey acidic protein. Biochem J. 2002; 368(Pt 1): 233–242.
  4. Kant K, Tomar AK, Sharma P, et al. Human epididymis protein 4 quantification and interaction network analysis in seminal plasma. Protein Pept Lett. 2019; 26(6): 458–465.
  5. James NE, Chichester C, Ribeiro JR. Beyond the biomarker: understanding the diverse roles of human epididymis protein 4 in the pathogenesis of epithelial ovarian cancer. Front Oncol. 2018; 8: 124.
  6. Zhu L, Zhuang H, Wang H, et al. Overexpression of HE4 (human epididymis protein 4) enhances proliferation, invasion and metastasis of ovarian cancer. Oncotarget. 2016; 7(1): 729–744.
  7. Wang Q, Wu Y, Zhang H, et al. Clinical value of serum HE4, CA125, CA72-4, and ROMA index for diagnosis of ovarian cancer and prediction of postoperative recurrence. Clin Lab. 2019; 65(4).
  8. Colombo N, Sessa C, du Bois A, et al. ESMO-ESGO Ovarian Cancer Consensus Conference Working Group. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. Ann Oncol. 2019; 30(5): 672–705.
  9. Shin KH, Kim HH, Kwon BSu, et al. Clinical usefulness of cancer antigen (CA) 125, human epididymis 4, and CA72-4 levels and risk of ovarian malignancy algorithm values for diagnosing ovarian tumors in korean patients with and without endometriosis. Ann Lab Med. 2020; 40(1): 40–47.
  10. Zhang L, Chen Y, Wang Ke. Comparison of CA125, HE4, and ROMA index for ovarian cancer diagnosis. Curr Probl Cancer. 2019; 43(2): 135–144.
  11. Chen X, Zhou H, Chen R, et al. Development of a multimarker assay for differential diagnosis of benign and malignant pelvic masses. Clin Chim Acta. 2015; 440: 57–63.
  12. Kim B, Park Y, Kim B, et al. Diagnostic performance of CA 125, HE4, and risk of Ovarian Malignancy Algorithm for ovarian cancer. J Clin Lab Anal. 2019; 33(1): e22624.
  13. Huy NV, Van Khoa Vo, Tam LeM, et al. Standard and optimal cut-off values of serum ca-125, HE4 and ROMA in preoperative prediction of ovarian cancer in Vietnam. Gynecol Oncol Rep. 2018; 25: 110–114.
  14. Shen Z, Zhu CC, Qian LL. Using HE4, RMI, ROMA and CPH-I in the differential diagnosis of adnexal masses. European Journal of Gynaecological Oncology. 2021; 42(1): 139.
  15. Farzaneh F, Honarvar Z, Yaraghi M, et al. Preoperative evaluation of risk of ovarian malignancy algorithm index in prediction of malignancy of adnexal masses. Iran Red Crescent Med J. 2014; 16(6): e17185.
  16. Lycke M, Kristjansdottir B, Sundfeldt K. A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index. Gynecol Oncol. 2018; 151(1): 159–165.
  17. Horała A, Swiatly A, Lorek J, et al. Assessment of diagnostic utility of multivariate diagnostic models in differential diagnosis of ovarian tumors. Ginekol Pol. 2018; 89(10): 568–572.
  18. McKendry K, Duff S, Huang Y, et al. The value of human epididymis 4, D-dimer, and fibrinogen compared with CA 125 alone in triaging women presenting with pelvic masses: a retrospective cohort study. Acta Obstet Gynecol Scand. 2021; 100(7): 1239–1247.
  19. Terlikowska KM, Dobrzycka B, Witkowska AM, et al. Preoperative HE4, CA125 and ROMA in the differential diagnosis of benign and malignant adnexal masses. J Ovarian Res. 2016; 9(1): 43.
  20. Bandiera E, Romani C, Specchia C, et al. Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management. Cancer Epidemiol Biomarkers Prev. 2011; 20(12): 2496–2506.
  21. Anton C, Carvalho FM, Oliveira EI, et al. A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses. Clinics (Sao Paulo). 2012; 67(5): 437–441.
  22. Shen Y, Zhao Li, Lu S. Diagnostic performance of HE4 and ROMA among Chinese women. Clin Chim Acta. 2020; 500: 42–46.
  23. Jordan SJ, Nagle CM, Coory MD, et al. Has the association between hysterectomy and ovarian cancer changed over time? A systematic review and meta-analysis. Eur J Cancer. 2013; 49(17): 3638–3647.
  24. Peres LC, Alberg AJ, Bandera EV, et al. Premenopausal hysterectomy and risk of ovarian cancer in African-American women. Am J Epidemiol. 2017; 186(1): 46–53.
  25. Hall MJ, Reid JE, Burbidge LA, et al. BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer. 2009; 115(10): 2222–2233.
  26. Wang D, Xie T, Xu J, et al. Genetic association between NFKB1 -94 ins/del ATTG Promoter Polymorphism and cancer risk: a meta-analysis of 42 case-control studies. Sci Rep. 2016; 6: 30220.
  27. Yang B, Fan S, Zhi X, et al. Geographical and ethnic distribution of MTHFR gene polymorphisms and their associations with diseases among Chinese population. Clin Genet. 2017; 92(3): 243–258.
  28. Zhang SY, Shi J. rs61764370 polymorphism of Kras and risk of cancer in Caucasian population: A meta-analysis. J Cancer Res Ther. 2016; 12(2): 699–704.
  29. Bolstad N, Øijordsbakken M, Nustad K, et al. Human epididymis protein 4 reference limits and natural variation in a Nordic reference population. Tumour Biol. 2012; 33(1): 141–148.
  30. Mokhtar Nm, Thevarajah M, Ma N, et al. Human epididymis protein 4 reference intervals in a multiethnic asian women population. Asian Pac J Cancer Prev. 2012; 13(12): 6391–6395.
  31. Gasiorowska E, Kluz T, Lipski D, et al. Human Epididymis Protein 4 (HE4) Reference Limits in Polish Population of Healthy Women, Pregnant Women, and Women with Benign Ovarian Tumors. Dis Markers. 2019; 2019: 3890906.
  32. Lowe KA, Shah C, Wallace E, et al. Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2008; 17(9): 2480–2487.
  33. Urban N, Thorpe J, Karlan BY, et al. Interpretation of single and serial measures of HE4 and CA125 in asymptomatic women at high risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2012; 21(11): 2087–2094.
  34. Escudero JM, Auge JM, Filella X, et al. Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases. Clin Chem. 2011; 57(11): 1534–1544.
  35. Chen Y, Mu X, Wang S, et al. WAP four-disulfide core domain protein 2 mediates the proliferation of human ovarian cancer cells through the regulation of growth- and apoptosis-associated genes. Oncol Rep. 2013; 29(1): 288–296.
  36. Zhuang H, Tan M, Liu J, et al. Human epididymis protein 4 in association with Annexin II promotes invasion and metastasis of ovarian cancer cells. Mol Cancer. 2014; 13: 243.
  37. Zhu YF, Gao GL, Tang SB, et al. Effect of WFDC 2 silencing on the proliferation, motility and invasion of human serous ovarian cancer cells in vitro. Asian Pac J Trop Med. 2013; 6(4): 265–272.
  38. Lu R, Sun X, Xiao R, et al. Human epididymis protein 4 (HE4) plays a key role in ovarian cancer cell adhesion and motility. Biochem Biophys Res Commun. 2012; 419(2): 274–280.